161 related articles for article (PubMed ID: 34589976)
21. Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics.
Arasanz H; Zuazo M; Bocanegra A; Gato M; Martínez-Aguillo M; Morilla I; Fernández G; Hernández B; López P; Alberdi N; Hernández C; Chocarro L; Teijeira L; Vera R; Kochan G; Escors D
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033028
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
Chen Y; Hu J; Bu F; Zhang H; Fei K; Zhang P
BMC Cancer; 2020 Jul; 20(1):707. PubMed ID: 32727409
[TBL] [Abstract][Full Text] [Related]
23. Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.
Lin M; Vanneste BGL; Yu Q; Chen Z; Peng J; Cai X
Transl Lung Cancer Res; 2021 Jul; 10(7):3276-3291. PubMed ID: 34430364
[TBL] [Abstract][Full Text] [Related]
24. Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.
Lo Russo G; Facchinetti F; Tiseo M; Garassino MC; Ferrara R
Curr Oncol Rep; 2020 Apr; 22(5):41. PubMed ID: 32296957
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Lo Russo G; Signorelli D; Garassino MC; Soria JC; Caramella C; Besse B
JCO Precis Oncol; 2020 Nov; 4():829-840. PubMed ID: 35050757
[TBL] [Abstract][Full Text] [Related]
26. Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis.
Ten Berge DMHJ; Hurkmans DP; den Besten I; Kloover JS; Mathijssen RHJ; Debets R; Smit EF; Aerts JGJV
ERJ Open Res; 2019 Oct; 5(4):. PubMed ID: 31857994
[TBL] [Abstract][Full Text] [Related]
27. Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
Abbar B; De Castelbajac V; Gougis P; Assoun S; Pluvy J; Tesmoingt C; Théou-Anton N; Cazes A; Namour C; Khalil A; Gounant V; Besse B; Zalcman G; Brosseau S
Lung Cancer; 2021 Feb; 152():109-118. PubMed ID: 33385736
[TBL] [Abstract][Full Text] [Related]
28. Lung metastasis and lymph node metastasis are risk factors for hyperprogressive disease in primary liver cancer patients treated with immune checkpoint inhibitors.
Xiao LS; Li QM; Hu CY; Cui H; Hong C; Huang CY; Li RN; Dong ZY; Zhu HB; Liu L
Ann Palliat Med; 2021 Nov; 10(11):11244-11254. PubMed ID: 34670386
[TBL] [Abstract][Full Text] [Related]
29. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis.
Zhao Z; Bian J; Zhang J; Zhang T; Lu X
Front Oncol; 2022; 12():843707. PubMed ID: 35992878
[TBL] [Abstract][Full Text] [Related]
30. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
[TBL] [Abstract][Full Text] [Related]
31. Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC).
Economopoulou P; Anastasiou M; Papaxoinis G; Spathas N; Spathis A; Oikonomopoulos N; Kotsantis I; Tsavaris O; Gkotzamanidou M; Gavrielatou N; Vagia E; Kyrodimos E; Gagari E; Giotakis E; Delides A; Psyrri A
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466719
[No Abstract] [Full Text] [Related]
32. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
Kim SH; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
[TBL] [Abstract][Full Text] [Related]
33. Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study.
Petrioli R; Mazzei MA; Giorgi S; Cesqui E; Gentili F; Francini G; Volterrani L; Francini E
Anticancer Drugs; 2020 Feb; 31(2):190-195. PubMed ID: 31850916
[TBL] [Abstract][Full Text] [Related]
34. The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Li J; Xiang C; Wang Y; Zhou Y; Cao S; Ling X; Ye J; Zheng J; Shao L; Zhong H; Han Y
Ann Transl Med; 2021 May; 9(9):779. PubMed ID: 34268392
[TBL] [Abstract][Full Text] [Related]
35. Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors.
Choi YJ; Kim T; Kim EY; Lee SH; Kwon DS; Chang YS
Thorac Cancer; 2020 Oct; 11(10):2793-2803. PubMed ID: 32779394
[TBL] [Abstract][Full Text] [Related]
36. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
37. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of
Castello A; Rossi S; Mazziotti E; Toschi L; Lopci E
J Nucl Med; 2020 Jun; 61(6):821-826. PubMed ID: 31862803
[TBL] [Abstract][Full Text] [Related]
38. Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study.
Long Y; Yang W; Bai Y; Tao H; Zhang F; Wang L; Yang B; Huang D; Han X; Hu Y
Cancer Cell Int; 2023 Sep; 23(1):224. PubMed ID: 37777758
[TBL] [Abstract][Full Text] [Related]
39. Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics.
Singla R; Gupta A; Batra U; Chaturvedi A; Rao A; Jajodia A
Indian J Radiol Imaging; 2021 Apr; 31(2):345-349. PubMed ID: 34556917
[No Abstract] [Full Text] [Related]
40. Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.
Shen P; Han L; Ba X; Qin K; Tu S
Front Pharmacol; 2021; 12():678409. PubMed ID: 34290608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
